Adicet Bio (ACET) Expected to Post Quarterly Earnings on Wednesday

Adicet Bio (NASDAQ:ACET) is expected to release its Q3 2026 results before the market opens on Wednesday, November 4th. Analysts expect the company to announce earnings of ($1.56) per share for the quarter. Investors are encouraged to explore the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Thursday, November 5, 2026 at 4:00 PM ET.

Adicet Bio (NASDAQ:ACET) last issued its quarterly earnings data on Wednesday, August 5th. The company reported ($1.99) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.69) by ($0.30). On average, analysts expect Adicet Bio to post ($6.76) EPS for the current fiscal year and ($5.64) EPS for the next fiscal year.

Adicet Bio Trading Down 3.3%

NASDAQ ACET opened at $3.81 on Wednesday. Adicet Bio has a one year low of $3.77 and a one year high of $14.56. The stock has a 50 day moving average price of $7.49 and a 200-day moving average price of $7.76.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on the stock. Guggenheim restated a “buy” rating and issued a $90.00 price target (down from $100.00) on shares of Adicet Bio in a research report on Thursday, August 6th. Benchmark reaffirmed a “buy” rating on shares of Adicet Bio in a research note on Tuesday, September 29th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Adicet Bio in a research report on Friday, August 21st. Wall Street Zen lowered shares of Adicet Bio from a “hold” rating to a “sell” rating in a research report on Saturday, October 17th. Finally, Jefferies Financial Group raised shares of Adicet Bio to a “strong-buy” rating in a research note on Tuesday, September 1st. Two investment analysts have rated the stock with a Strong Buy rating, five have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $37.80.

About Adicet Bio

Adicet Bio, Inc is a clinical-stage biotechnology company developing allogeneic T-cell therapies for the treatment of cancer. The company’s platform is focused on genetically engineered gamma delta T cells, an immune-cell type that can recognize and attack abnormal cells while potentially offering advantages for off-the-shelf cell therapy development.

Adicet’s product candidates are designed to incorporate chimeric antigen receptors and other modifications intended to improve tumor targeting, persistence, and activity.